シンポジウム

Symposia

Sunday, 26 March 10:40 ～ 11:45 / 13:15 ～ 17:40
Plenary Lecture: Room B Tachibana Conference Hall, Sendai International Center (Conference building 2F)

Invited Poster Presentation: Room G Meeting Room 4, Sendai International Center (Conference building 2F)

第3回国際創薬シンポジウム ISMS
3rd International Symposium for Medicinal Sciences
10:40 ～ 10:45
Opening Remark 

Chairman: Akira OTAKA（Tokushima University）

10:45 ～ 11:45
Plenary Lecture 1 ISMS-PL01

Chairman: Tsuneaki SAKATA（Shionogi & Co., Ltd.）

Robot Scientists: Automating Drug Design
Ross D. KING（University of Manchester）

13:15 ～ 14:15
Plenary Lecture 2 ISMS-PL02

Chairman: Tatsuhiko KODAMA（The University of Tokyo）

Recent Advances in cryo-EM: Applications to Drug Discovery
Sriram SUBRAMANIAM（National Cancer Institute, NIH）

14:20 ～ 17:40
Invited Poster Presentation
14:20 ～ 16:00

Short Presentation for Invited Poster Presentation

16:00 ～ 17:40

Poster Presentation
Discussion   Odd Number: 16:00 ～ 16:50
Even Number: 16:50 ～ 17:40

26G-ISMS01 Unstructured Protein : A New Approach for Drug Discovery○ Takenao ODAGAMI1, Yoichiro HIROSE1, Yoshimasa IMAMURA1, Akira KATOH1,
Tadashi MISHINA1, Hiroyuki KOUJI1（1Research & Development, PRISM BioLab Co., Ltd.）
26G-ISMS02 Development of Macrocyclic Peptide Targeting Ebola Glycoprotein○ Shiori UMEMOTO1, Junki MARUYAMA2, Ayato TAKADA2, Hiroaki SUGA1（1Department
2of Chemistry, Graduate School of Science, The University of Tokyo, Department of Global Epidemiology, ResearchCenter for Zoonosis Control, Hokkaido University）

26G-ISMS03 Combinatorial Solid-Phase Synthesis and Biological Evaluation of Cyclodepsipeptide
Destruxin B as a Negative Regulator for Osteoclast Morphology○ Hiroshi SATO1,2, Masahito YOSHIDA1, Hayato MURASE3, Hiroshi NAKAGAWA3,
Takayuki DOI1（1Graduate School of Pharmaceutical Sciences, Tohoku University, 2Mitsubishi Tanabe Pharma
Corporation,3

Department of Applied Biological Chemistry, Chubu University）

26G-ISMS04 SAR Exploration of Selective Kinase Inhibitors based on the “Head-to-Tail” Approach:Discovery of PI4KIIIα Inhibitors Bearing Diverse Scaffolds○ Satoru NOJI1, Noriyoshi SEKI1, Takaki MAEBA1, Takayuki SAKAI1, Eiichi WATANABE1,
Katsuya MAEDA1, Kyoko FUKUSHIMA1, Toru NOGUCHI1, Kazuya OGAWA1,
Yukiyo TOYONAGA1, Tamotsu NEGORO1, Hisashi KAWASAKI1, Makoto SHIOZAKI1
1（ Central Pharmaceutical Research Institute, Japan Tobacco Inc.）– 25 –

26G-ISMS05 Search for Anti-leukemic Drugs Targeting the Transcription Factor Runx1 by INTENDD○ Masaaki SHIINA1, Shiho BABA1, Akiko UCHIYAMA1, Chikako OKADA1,
Takeshi TANAKA2, Ken IKEDA2, Shigetsugu KAWAKITA2, Takao MATSUZAKI2,
Hirotsugu KOMATSU2, Masato HOSODA2, Kazuhiro OGATA1（1Yokohama City University,
2

Graduate School of Medicine, Interprotein Corporation）

26G-ISMS06 Evaluation of Novel Anti-Dengue Candidates Using In Silico and In Vitro Approaches○ Yu-Shi TIAN1, Hitoshi MATSUDA2, Xinzhe LIU2, Norihito KAWASHITA2,3,
Tatsuya TAKAGI2,3（1Graduate School of Information Science and Technology, Osaka University, 2Graduate
3

School of Pharmaceutical Sciences, Osaka University, Graduate School of Information Science and Technology,
Osaka University Research Institute for Microbial Diseases）

26G-ISMS07 Development and Construction of an Original Compound Library for CNS Drug
Discovery: Combining Computational and Wet Data to Enhance CNS Drug-likeness○ Daiju HASEGAWA1（1Medicinal Chemistry, Neurology Tsukuba Research Department, Discovery, Medicine
Creation, Neurology Business Group, Eisai Co., Lid.）

26G-ISMS08 Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[1,2-b ]Pyridazine- based p38 MAP Kinase Inhibitors○ Akira KAIEDA1, Masashi TAKAHASHI1, Takafumi TAKAI1, Masayuki GOTO1,
Takahiro MIYAZAKI1, Yuri HORI1, Satoko UNNO1, Tomohiro KAWAMOTO1,
Toshimasa TANAKA1, Sachiko ITONO1, Terufumi TAKAGI1, Teruki HAMADA1,
Mikio SHIRASAKI1, Kengo OKADA1, Gyorgy SNELL2, Ken BRAGSTAD2, Bi-Ching SANG2,
Osamu UCHIKAWA1, Seiji MIWATASHI1（1Takeda Pharmaceutical Company Limited, 2Takeda
California, Inc.）

26G-ISMS09 Flow Chemistry: New Horizons in Chemical Space for the Creation of Next Generation
Libraries
Daniel BLANCO-ANIA3, Sagar Ashok GAWADE1, Luuk MAARTENSE1,
Roel VERLEIJSDONK1, Remco MERKX2, Huib OVAA2, Floris RUTJES1, Marjon BOLSTER3,
Luc ZWINKELS3, Joeri SCHEIDT3, Pauline van MEURS3, Jorg BENNINGSHOF3,○ Norimasa MORITA3（1Radboud University, 2Leiden UMC (Former NKI), 3Mercachem）
26G-ISMS10 Transition Metal-Free, Tryptophan-Selective Bioconjugation of Proteins○ Kounosuke OISAKI1, Yohei SEKI1, Takashi ISHIYAMA1, Daisuke SASAKI1,2, Junpei ABE1,
Yohei SOHMA1,2, Motomu KANAI1,2（1Graduate School of Pharmaceutical Sciences, The University of
2Tokyo, JST, ERATO Kanai Life Science Catalysis Project）

26G-ISMS11 Total Synthesis of Halichondrin A and C○ Akihiko YAMAMOTO1, Atsushi UEDA1, Paul BRÉMOND1, Paolo S. TISENI1,
Daisuke KATO1, Yoshito KISHI1（1Department of Chemistry and Chemical Biology, Harvard University）
26G-ISMS12 Parallel Fluorescent Probe Synthesis Based on the Large-scale Preparation of BODIPYFL Propionic Acid
○ Taisuke KATOH1, Masato YOSHIKAWA1, Takeshi YAMAMOTO1, Ryosuke ARAI1,
Noriyuki NII1, Yoshihide TOMATA1, Shinkichi SUZUKI1, Ryoukichi KOYAMA1,
Nobuyuki NEGORO1, Takatoshi YOGO1（1Pharmaceutical Research Division, Takeda Pharmaceutical
Company, Ltd）

26G-ISMS13 Improvement in Pharmacokinetics and In Vivo Activity of Somatostatin by Chemical
Glycosylation○ Hirofumi OCHIAI1, Jun IGARASHI1, Hayato SAIJO1, Takahiro YAMAMOTO1,
Yuji NISHIUCHI1, Akio KANATANI1, Taiji SHIMODA1（1GlyTech, Inc.）
26G-ISMS14 Development of an Oxidative Mizoroki-Heck Reaction for Late-stage C-HFunctionalization of Complex Molecules and Application to Pharmaceutical Studies○ Kenji WATANABE1, Amrita DAS1, Takumi KIMIJIMA1, Tomohiro YAMASHITA1,
Kazuhide INOUE1, Makoto TSUDA1, Takashi OHSHIMA1（1Graduate School of Pharmaceutical
Sciences, Kyushu University）– 26 –

26G-ISMS15 Functional Characterization of Acetylcholine Receptors in Human HippocampusDerived Neurons○ Kazuyuki FUKUSHIMA1, Kazuto YAMAZAKI2, Norimasa MIYAMOTO3,
Kohei SAWADA3（1Neurology Tsukuba Research Department, Discovery, Medicine Creation, Neurology
2

3

Business Group, Eisai Co., Ltd., Technology Cross Point Laboratory, hhc Data Creation Center, Eisai Co., Ltd., Global
CV Assessment, BA CFU, Medicine Development Center, Eisai Co., Ltd.）

26G-ISMS16 Analgesic Effect of Novel 11 β -HSD1 Inhibitor ASP3662 and its Mechanism of Action
in a Spinal Nerve Ligation Model of Neuropathic Pain
○ Tetsuo KISO1, Toshihiro SEKIZAWA1, Mina TSUKAMOTO1, Junko YARIMIZU1,
Shuichiro KAKIMOTO1（1Drug Discovery Research, Astellas Pharma Inc.）
26G-ISMS17 Atomic-Scale Investigation on Acetaminophen Crystals with Stable and Metastable
Phases by Frequency Modulation Atomic Force Microscopy in Aqueous Solution○ Naritaka KOBAYASHI1, Kazuki OKANO2, Yoichiro MORI3, Shun FUKUKITA3,
Mihoko MARUYAMA4, Hiroaki ADACHI3,5, Kazufumi TAKANO4,5, Satoshi MURAKAMI5,6,
Hiroyoshi MATSUMURA5,7, Tsuyoshi INOUE3,5, Masashi YOSHIMURA5,8, Yusuke MORI3,5,
Seiichiro NAKABAYASHI1, Hiroshi YOSHIKAWA1,3（1Graduate School of Science and Engineering,
2

3

Saitama University, Faculty of Science, Saitama University, Graduate School of Engineering, Osaka University,
4
5
6
Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, SOSHO, Inc., Graduate School
7of Bioscience and Biotechnology, Tokyo Institute of Technology, College of Life Science, Ritsumeikan University,
8
Institute of Laser Engineering, Osaka University）

26G-ISMS18 Anti-inflammatory Flavan-dihydrochalcones with Unprecedented Carbon Skeletonsfrom Daemonorops Draco○ Ping-Chung KUO1, Hsin-Yi HUNG1, Tsong-Long HWANG2, Tian-Shung WU1（1 School of
Pharmacy, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 
2Graduate Institute of Natural Products, College of Medicine, Chang Gung University）

26G-ISMS19 Development of a Fully Automated HPLC System (ASAPrepTM) Designed for Multiple
Compound Purifications○ Chie KUSHIBE1, Katsuhiko MIWA1, Hidetoshi TERADA2, Yuji KATSUYAMA2（1Medicinal
2

Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Life
Science Business Department, Analytical & Measurement Instruments Division, Shimadzu Corporation）

26G-ISMS20 Discovery of a Novel PDE10A Inhibitor as Highly Effective for Schizophrenia○ Yoichi KADOH1, Takehiko MATSUMURA1, Yoshihito TANAKA1, Mitsuya HONGU1,
Haruko MIYOSHI1, Mayumi KIMURA1, Kei TAKEDOMI1, Kenji OMORI1, Jun KOTERA1,Takashi SASAKI1, Kiichi TANAKA1, Keiko MIWA1, Tamaki KOBAYASHI1,
Hiroyuki TANIGUCHI1, Taketoshi ISHII1, Yumi WATANABE1, Haruna ITODA1,
Rikiya OHASHI1, Kouki KOJIMA1, Masaya FUKUDA1, Saori SATO1, Itsuko NAKAMURA1,
Toshiaki SAKAMOTO1, Toshiyuki HIMIYAMA1, Masataka HIKOTA1, Eiji KAWANISHI1
1（ Mitsubishi Tanabe Pharma Corporation）

26G-ISMS21 Nucleic Acid Drugs Large Scale Manufacturing and Specification Assay– Equivalency
Solid Phase versus AJIPHASE® and Oligonucleotide Sequences Confirmation for IND
and NDA○ Satoshi INOUE1, Hirokazu NANKAI1, Emi SAITO1, Hideaki SATO1, Kazuhiko YUYAMA1
1（ GeneDesign, Inc.）

26G-ISMS22 Amycolamicin, a Novel Antibiotic as a Promising Candidate for Clostridium Difficile
Infection: Antibacterial Activity, Mode of Action, and In Vivo Efficacy○ Yoshimasa ISHIZAKI1, Kazushige SASAKI1, Hideki HASHIZUME1, Chigusa HAYASHI1,
Kunio INOUE1, Hayamitsu ADACHI1, Yoshiaki TAKAHASHI1, Masayuki IGARASHI1,
Yoshio NISHIMURA1, Yuzuru AKAMATSU1, Akio NOMOTO1, Masakatsu SHIBASAKI1
1（ Institute of Microbial Chemistry (BIKAKEN)）

26G-ISMS23 Identification and Optimization of a Novel Series of Tetrahydroisoquinoline Derivatives
as an Orally Active MGAT2 Inhibitor○ Tsuyoshi BUSUJIMA1, Hiroaki TANAKA2, Eiji MUNETOMO3, Kiyokazu KITANO3,
Masako SAITO3（1Pharamceutical Science Laboratories, 2Chemistry Laboratories, 3Pharmacology Laboratories,
Taisho Pharmaceutical Co., Ltd.）– 27 –

26G-ISMS24 Discovery of Novel Fluoroquinolone Antibiotics WFQ-101 and Its Optimization Study○ Tatsuya HIRANO1, Tomohiko KINOSHITA1, Daichi KAZAMORI1, Satoshi INOUE1,
Kouji NISHIMURA1, Asuka SAKURAI1, Ayuka SASAKI1, Yasuhiro KURAMOTO1,
Hirotaka AMANO1, Akira YAZAKI1（1Drug Discovery Laboratory, Wakunaga Pharmaceutical Co., Ltd.）
26G-ISMS25 Anti-CTLA-4 Antibody scFv Producing Recombinant Bifidobacterium Secretes CTLA4 Blocker Specifically Inside Hypoxic Tumor and Suppresses Tumor Growth inSyngeneic Mice Model○ Shiro KATAOKA1, Koichiro SHIOYA1, Li WANG1, Tomio MATSUMURA1,
Hitomi SHIMIZU1, Yasuyoshi KANARI1, Yuji SEKI1, Yuko SHIMATANI1,
Minoru FUJIMORI2, Shun'ichiro TANIGUCHI3（1Anaeropharma Science, Inc., 19-8, Nihonbashi Kabuto2cho, Chuo-ku, Tokyo 103-0026, Japan, Department of Breast Surgery, Tokyo Medical University Ibaraki Medical
3
Center, Ibaraki, Japan, Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine）

26G-ISMS26 Structural Basis for Activation of Neisseria Meningitides Elongation Factor P with
Arginine-32 Rhamnosylation by EarP
○ Toru SENGOKU1（1RIKEN Structural Biology Laboratory）
26G-ISMS27 Design, Synthesis and Biological Evaluation of a Novel Series of Peripheral-selective
Noradrenaline Reuptake Inhibitor, Part I -Lead Series Discovery and Biological
Concept Validation○ Ikuo FUJIMORI1, Tomoya YUKAWA1, Taku KAMEI1, Yoshihisa NAKADA1,
Nobuki SAKAUCHI1, Masami YAMADA1, Yusuke OHBA1, Maiko TAKIGUCHI1,
Masako KUNO1, Izumi KAMO1, Hideyuki NAKAGAWA1, Teruki HAMADA1,
Tomoko IGARI1, Teruaki OKUDA1, Satoshi YAMAMOTO1, Tetsuya TSUKAMOTO1, Yuji
ISHICHI1, Hiroyuki UENO1（1Takeda Pharmaceutical Company Limited）
26G-ISMS28 Design, Synthesis and Biological Evaluation of a Novel Series of Peripheral-selective
Noradrenaline Reuptake Inhibitor, Part II -Lead Optimization with Avoiding P-gp
Substrate and Genetic Polymorphism○ Tomoya YUKAWA1, Ikuo FUJIMORI1, Taku KAMEI1, Yoshihisa NAKADA1,
Nobuki SAKAUCHI1, Masami YAMADA1, Yusuke OHBA1, Hiroyuki UENO1,
Maiko TAKIGUCHI1, Masako KUNO1, Izumi KAMO1, Hideyuki NAKAGAWA1,
Yasushi FUJIOKA1, Tomoko IGARI1, Yuji ISHICHI1, Tetsuya TSUKAMOTO1
1（ Takeda Pharmaceutical Company Limited）

26G-ISMS29 Ex Vivo Gene-manipulated Mature Adipocytes: Novel Gene Therapy Medicine for
Sustained Protein Replacement Therapy of Variety of Intractable Diseases○ Masayuki KURODA1, Hideaki BUJO2, Koutaro YOKOTE3, Yasushi SAITO4,
Masayuki ASO5（1Center for Advanced Medicine, Chiba University, 2Department of Clinical Laboratory
3

Medicine, Toho University Medical Center Sakura Hospital, Department of Clinical Cell Biology and Medicine,
4
Graduate School of Medicine, Chiba University, Superintendent of the hospital bureau, City Hall of Chiba,
5CellGenTech, Inc.）

26G-ISMS30 Application of Novel Highly Immunodeficient Mice for Patient Derived Xenograft(PDX) Model and Evaluation of Anticancer Therapy○ Seiji OKADA1, Kulthida VAETEEWOOTTACAHRN1, Hiroki GOTO1, Ryusho KARIYA1
1（ Center for AIDS Research and Graduate School of Medical Sciences, Kumamoto University）

26G-ISMS31 The Unbound Concentration of Multimodal Drugs in the Assay Medium Used in theMulti-electrode Array System for Cardiac Risk Assessment with iPS Cell-derived
Cardiomyocytes○ Takashi YOSHINAGA1,4, Raku SINKYO2, Kiyomi KIKUCHI2, Tomohiko TANIGUCHI1,4,
Yuko SEKINO3,4, Kohei SAWADA1,4（1Global CV Assessment, Eisai Co., Ltd., 2Global DMPK, Eisai Co., Ltd.,
3

4

Division of Pharmacology, National Institute of Health Sciences, Japan iPS Cardiac Safety Assessment (JiCSA)）– 28 –

26G-ISMS32 Discovery of ASP3026, a Potent and Selective Anaplastic Lymphoma Kinase (ALK)
Inhibitor○ Kazuhiko IIKUBO1, Yutaka KONDOH1, Itsuro SHIMADA1, Takahiro MATSUYA1,
Kenichi MORI1, Yoko UENO1, Sadao KUROMITSU1, Minoru OKADA1（1Astellas Pharma Inc.）
26G-ISMS33 Immune Profiling with a New NGS-based Repertoire Analysis○ Takaji MATSUTANI1, Kazutaka KITAURA1, Hiroshi YAMASHITA1, Hitomi AYABE1,
Hiroyuki SATO1, Yuichi MORITA1, Tadasu SHINI2,3, Ryuji SUZUKI1,3（1Repertoire Genesis
2

3

Incorporation, BITS. Co., Ltd., Clinical Research Center for Rheumatology and Allergy, Sagamihara National
Hospital）

26G-ISMS34 Cyclodextrin-based Supramolecular Drug Carriers and Active Pharmaceutical
Ingredients○ Taishi HIGASHI1, Keiichi MOTOYAMA1, Hidetoshi ARIMA1,2（1Department of Physical2

Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Program for Leading Graduate
Schools “HIGO (Health life science: Interdisciplinary and Glocal Oriented) Program”, Kumamoto University）

26G-ISMS35 Antifungal Activities and Nonclinical Pharmacokinetics of APX001A/APX001 (E1210/
E1211), a New Broad-Spectrum Antifungal, with a New Mode of Action○ Takaaki HORII1（1Global Health Research Section, hhc Data Creation Center, Eisai Co., Ltd.）
26G-ISMS36 Synthesis and Evaluation of Potent, Orally Available, Well-balanced EP2 and EP3 Dual
Agonists○ Akihiro KINOSHITA1, Masato HIGASHINO1, Koji YOSHIDA1, Yoshiyuki ARATANI1,
Akito KAKUUCHI1, Keisuke HANADA1, Hiroyuki TAKEDA1, Toshikiko NISHIYAMA1,
Hidekazu MATSUYA1, Kazuyuki OHMOTO1（1Medicinal Chemistry Research Laboratories, Ono
Pharmaceutical Co., Ltd.）

26G-ISMS37 Novel Development of Chemotherapy for Relapsed and Refractory AML Based on thePromising Functional Mechanism of Cytidine Analog, DFP-10917○ Masakazu FUKUSHIMA1, Kenzo IIZUKA1, Chung ZHANG1, Cheng JIN1, Kiyoshi ESHIMA1
1（ Division of Research and Development, Delta-Fly Pharma, Inc.）

26G-ISMS38 System-wide Temporal Characterization of the Phosphoproteome of Non-small-cell
Lung Cancer Cells Treated with Erlotinib○ Adachi JUN1, Yuichi ABE1, Maiko SHIMIZU1, Marina KISHIDA1, Ayako SATO1,
Takeshi TOMONAGA1（1Laboratory of Proteome Research National Institutes of Biomedical Innovation,
Health and Nutrition）

26G-ISMS39 Identification of WAC-224, a Novel Anticancer Quinolone as a Human Topoisomerase
II Inhibitor○ Tomonori YAMAGUCHI1, Kenji ITOH1, Taichi UESHIMA1, Rumiko SHIMABARA1,
Yohei KAWAKUBO1, Masayuki SATO1, Junpei YAMASHITA1, Tatsuya HIRANO1,
Akira YAZAKI1（1Drug Discovery Laboratory, Wakunaga Pharmaceutical Co., Ltd.）
26G-ISMS40 Lenvatinib Mesilate (LEN) Enhanced Antitumor Activity of a PD-1 Blockade Agent byPotentiating Th1 Immune Response○ Yu KATO1, Xingfeng BAO2, Shannon MACGRATH2, Kimiyo TABATA1, Yusaku HORI1,
Sho TACHINO1, Mark MATIJEVICI2, Yasuhiro FUNAHASHI1, Junji MATSUI1（1Eisai Co., Ltd.,
2

Tsukuba, Ibaraki, Japan, Eisai Inc. Andover, MA, USA）

26G-ISMS41 Identification of Blood-based Gene Expression Biomarkers for Major Depressive and
Bipolar Disorders○ Seiji NAKAMURA1, Hiroaki HORI2, Yohei ISHIZAWA1, Kenichi MATSUBARA1,
Ryo MATOBA1, Hiroshi KUNUGI2（1DNA Chip Research Inc., 2Department of Mental Disorder Research,
National Institute of Neuroscience, National Center of Neurology and Psychiatry）– 29 –

26G-ISMS42 Anti-Helicobacter Pylori Activity of a Novel Derivative of Intervenolin○ Tomokazu OHISHI1, Toru MASUDA1, Shun-ichi OHBA1, Chigusa HAYASHI2,
Hikaru ABE3, Masayuki IGARASHI2, Takumi WATANABE3 , Daniel Ken INAOKA4,
Kiyoshi KITA5, Masakatsu SHIBASAKI3, Manabu KAWADA1,6（1Institute of Microbial Chemistry
2(BIKAKEN), Numazu, Microbial Chemistry Research Foundation, Institute of Microbial Chemistry (BIKAKEN),
3
Laboratory of Microbiology, Microbial Chemistry Research Foundation, Institute of Microbial Chemistry (BIKAKEN),
4
Laboratory of Synthetic Organic Chemistry, Microbial Chemistry Research Foundation, Center for International
5
Collaborative Research, Nagasaki University, School of Tropical Medicine and Global Health, Nagasaki University,
6
Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation）

26G-ISMS43 Discovery of Novel 5,6,7,8-tetrahydro[1,2,4]Triazolo[4,3-a ]Pyridine Derivatives asγ-secretase Modulators○ Takafumi TAKAI1, Tatsuki KOIKE1, Minoru NAKAMURA1, Yasutaka HOASHI1,
Yoshihide TOMATA1, Sachie MORIMOTO1, Yuichi KAJITA1, Toshiro YAMASHITA1,
Naohiro TAYA1, Tetsuya TSUKAMOTO1, Tomomichi WATANABE1, Koji MURAKAMI1,
Tomoko IGARI1, Makoto KAMATA1（1Takeda Pharmaceutical Company Limited）
26G-ISMS44 Regulatory Science for R&D Promotion of Innovative Pharmaceuticals*
Kazuhiko MORI1, Takao YAMORI2, ○ Toru KAWANISHI3, Takao INOUE4（1Ministry of Health,2

3

Labor and Welfare (MHLW), Pharmaceuticals and Medical Devices Agency (PMDA), National Institute of Health4
Sciences (NIHS), Japan Agency Medical Research and Development (AMED)）– 30 –